Journal of Thrombosis and Thrombolysis

, Volume 36, Issue 2, pp 187–194 | Cite as

Measuring the anticoagulant effects of target specific oral anticoagulants—reasons, methods and current limitations

  • Helen Mani
  • Alexander Kasper
  • Edelgard Lindhoff-Last


To simplify and optimize oral anticoagulation, new target-specific oral anticoagulants (TSOAs) have been developed. The direct thrombin-inhibitor dabigatran and the direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban are the first such compounds to receive approval in certain countries for various indications. Due to the predictable pharmacokinetic and pharmacodynamic profiles of these drugs, routine monitoring of patients receiving TSOA therapy has not been considered necessary. However, it has now been realized that in routine clinical settings, there are several situations where it may be prudent to assess the level of TSOA anticoagulation. Several studies evaluating the influence of TSOAs on various coagulation assays have been performed to identify systems that can be used to monitor these drugs. With a particular focus on dabigatran and rivaroxaban, we will describe and discuss the potential of several methods for measuring the anticoagulant effect of TSOAs, as well as their methodological limitations and the restrictions in transferring their results into clinical context.


Rivaroxaban Dabigatran Coagulation assays Monitoring 


  1. 1.
    Bingham JB, Meyer OO, Pohle FJ et al (1941) Studies on hemorrhagic agent 3,3′-methylenebis (4-hydroxy-coumarin): I. Ist effect on the prothrombin and coagulation time of the blood of dogs and humans. Am J Med Sci 202:563–577CrossRefGoogle Scholar
  2. 2.
    Ageno W, Gallus AS, Wittkowsky A et al (2012) Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e44S–e88SPubMedCrossRefGoogle Scholar
  3. 3.
    Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883–891PubMedCrossRefGoogle Scholar
  4. 4.
    Conolly SJ, Ezekowitz MD et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151CrossRefGoogle Scholar
  5. 5.
    Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992PubMedCrossRefGoogle Scholar
  6. 6.
    Ogilvie IM et al (2010) Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 123(7):638–645.e4PubMedCrossRefGoogle Scholar
  7. 7.
    EINSTEIN Investigators (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363(26):2499–2510CrossRefGoogle Scholar
  8. 8.
    Schulman S, Kearon C, Kakkar AK et al (2009) Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 361(24):2342–2352PubMedCrossRefGoogle Scholar
  9. 9.
    EINSTEIN-PE Investigators (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366(14):1287–1297CrossRefGoogle Scholar
  10. 10.
    Healey JS, Eikelboom J, Douketis J et al (2012) Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the randomized evaluation of long-term anticoagulation therapy (RE-LY) randomized trial. Circulation 126(3):343–348PubMedCrossRefGoogle Scholar
  11. 11.
    Baglin T, Hillarp A, Tripodi A et al (2013) Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. doi: 10.1111/jth.12149 Google Scholar
  12. 12.
    Harenberg J, Marx S, Weiss C et al (2012) Subcommittee on Control of Anticoagulation of the ISTH. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost 10(7):1433–1436PubMedCrossRefGoogle Scholar
  13. 13.
    International Committee on Thrombosis Haemostasis/International Committee for Standardization in Haematology (1979) Prothrombin time standardisation: report of the expert panel on oral anticoagulant control. Thromb Haemost 42:1073–1114Google Scholar
  14. 14.
    World Health Organization (1983) Requirements for thromboplastins and plasma used to control oral anticoagulant therapy (Requirements for Biological Substances no. 30, revised 1982) WHO Expert Committee on Biological Stan- dardization. Thirty-Third report. Annex 3, WHO Technical Report Series, no. 687. World Health Organization, GenevaGoogle Scholar
  15. 15.
    Holbrook A, Schulman S, Witt DM et al (2012) Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e152S–e184SPubMedCrossRefGoogle Scholar
  16. 16.
    Lansberg MG, O′Donnell MJ, Khatri P (2012) Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e601S–e636SPubMedCrossRefGoogle Scholar
  17. 17.
    You JJ, Singer DE, Howard PA et al (2012) Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e531S–e575SPubMedCrossRefGoogle Scholar
  18. 18.
    Kearon C, Aki EA, Comerota AJ et al (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest 141(2 Suppl):e419S–e494SPubMedCrossRefGoogle Scholar
  19. 19.
    Mueck W, Eriksson BI, Bauer KA et al (2008) Population pharmacokinetics and pharmacodynamics of rivaroxaban–an oral, direct factor Xa inhibitor-in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 47(3):203–216PubMedCrossRefGoogle Scholar
  20. 20.
    Perzborn E, Roehrig S, Straub A et al (2010) Rivaroxaban: a new oral factor Xa inhibitor. Arterioscler Thromb Vasc Biol 30(3):376–381PubMedCrossRefGoogle Scholar
  21. 21.
    Wienen W, Stassen JM, Priepke H et al (2007) In-vitro profile and ex vivo anticoagulantactivity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost 98:155–162PubMedGoogle Scholar
  22. 22.
    Samama MM, Martinoli JL, LeFlem L et al (2010) Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost 103(4):815–825PubMedCrossRefGoogle Scholar
  23. 23.
    van Ryn J, Stangier J, Haertter S et al (2010) Dabigatran etexilate—a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103(6):1116–1127PubMedCrossRefGoogle Scholar
  24. 24.
    Stangier J et al (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64(3):292–303PubMedCrossRefGoogle Scholar
  25. 25.
    Perzborn E, Strassburger J, Wilmen A et al (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59–7939–an oral, direct Factor Xa inhibitor. J Thromb Haemost 3(3):514–521PubMedCrossRefGoogle Scholar
  26. 26.
    Tripodi A, Chantarangkul V, Guinet C, Samama MM (2011) The international normalized ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost 9(1):226–228PubMedCrossRefGoogle Scholar
  27. 27.
    Samama MM, Guinet C (2011) Laboratory assessment of new anticoagulants. Clin Chem Lab Med 49(5):761–772PubMedCrossRefGoogle Scholar
  28. 28.
    Lindhoff-Last E, Samama MM, Ortel TL et al (2010) Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 32(6):673–679PubMedCrossRefGoogle Scholar
  29. 29.
    Samama MM, Contant G, Spiro TE et al (2012) Rivaroxaban prothrombin time field trial laboratories. Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost 18(2):150–158PubMedCrossRefGoogle Scholar
  30. 30.
    Kubitza D, Becka M, Voith B et al (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59–7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78(4):412–421PubMedCrossRefGoogle Scholar
  31. 31.
    Douxfils J et al (2012) Assessment of the impact of rivaroxaban on coagulation assays: laboratory recommendations for the monitoring of rivaroxaban and review of the literature. Thromb Res. doi: 10.1016/j.thromres.2012.09.004 PubMedGoogle Scholar
  32. 32.
    EMA-Rivaroxaban (2012) Summary of product characteristicsGoogle Scholar
  33. 33.
    Mani H et al (2011) Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost 106(1):156–164PubMedCrossRefGoogle Scholar
  34. 34.
    Tobu M, Iqbal O, Hoppensteadt D et al (2004) Anti-Xa and anti-IIa drugs alter international normalized ratio measurements: potential problems in the monitoring of oral anticoagulants. Clin Appl Thromb Hemost 10:301–309PubMedCrossRefGoogle Scholar
  35. 35.
    Lindahl TL et al (2011) Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost 105(2):371–378PubMedCrossRefGoogle Scholar
  36. 36.
    Douxfils J et al (2012) Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost 107(5):985–997PubMedCrossRefGoogle Scholar
  37. 37.
    Herth N, Mani H, Wenger F, et al. (2011) Dabigatran influences ex vivo global coagulation assays in dependence of time of drug intake. Hämostaseologie 1(A89): P17.5Google Scholar
  38. 38.
    Ezekowitz MD, Reilly PA, Nehmiz G et al (2007) Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol 100:1419–1426PubMedCrossRefGoogle Scholar
  39. 39.
    Liesenfeld KH, Schäfer HG, Trocóniz IF et al (2006) Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: apopulation model analysis. Br J Clin Pharmacol 62:527–537PubMedCrossRefGoogle Scholar
  40. 40.
    EMA-Dabigatran (2011) SPCGoogle Scholar
  41. 41.
    Baglin T et al (2012) Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol. doi: 10.1111/bjh.12052 Google Scholar
  42. 42.
    Stangier J, Stähle H, Rathgen K et al (2008) Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 47:47–59PubMedCrossRefGoogle Scholar
  43. 43.
    Stangier J, Feuring M (2012) Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 23(2):138–143PubMedCrossRefGoogle Scholar
  44. 44.
    Green L, Lawrie AS, Patel R et al (2012) The effect of total hip/knee replacement surgery and prophylactic dabigatran on thrombin generation and coagulation parameters. Thromb Res 130(5):775–779PubMedCrossRefGoogle Scholar
  45. 45.
    Curvers J, van de Kerkhof D, Stroobants AK et al (2012) Measuring direct thrombin inhibitors with routine and dedicated coagulation assays: which assay is helpful? Am J Clin Pathol 138(4):551–558PubMedCrossRefGoogle Scholar
  46. 46.
    Freyburger G et al (2011) Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 127(5):457–465PubMedCrossRefGoogle Scholar
  47. 47.
    Avecilla ST, Ferrell C, Chandler WL, Reyes M (2012) Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy. Am J Clin Pathol 137(4):572–574PubMedCrossRefGoogle Scholar
  48. 48.
    Lefemine AA, Lewis M (1985) Activated clotting time for control of anticoagulation during surgery. Am Surg 51(5):274–278PubMedGoogle Scholar
  49. 49.
    Nowak G (2003) The ecarin clotting time, a universal method to quantify direct thrombin inhibitors. Pathophysiol Haemost Thromb 33(4):173–183PubMedCrossRefGoogle Scholar
  50. 50.
    Lange U, Nowak G, Bucha E (2004) Ecarin chromogenic assay–a new method for quantitative determination of direct thrombin inhibitors like hirudin. Pathophysiol Haemost Thromb 33(4):184–191CrossRefGoogle Scholar
  51. 51.
    Klaeffling C, Piechottka G, Daemgen-von Brevern G et al (2006) Development and clinical evaluation of two chromogenic substrate methods for monitoring fondaparinux sodium. Ther Drug Monit 28:375–381PubMedCrossRefGoogle Scholar
  52. 52.
    Samama MM et al (2012) Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 107(2):379–387PubMedCrossRefGoogle Scholar
  53. 53.
    Harenberg J, Krämer R, Giese C et al (2011) Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis 32(3):267–271PubMedCrossRefGoogle Scholar
  54. 54.
    Asmis LM, Alberio L, Angelillo-Scherrer A et al (2012) Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res 129(4):492–498PubMedCrossRefGoogle Scholar
  55. 55.
    Mani H, Rohde G, Stratmann G et al (2012) Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 108(1):191–198PubMedCrossRefGoogle Scholar
  56. 56.
    Salmela B, Joutsi-Korhonen L, Saarela E, Lassila R (2010) Comparison of monitoring methods for lepirudin: impact of warfarin and lupus anticoagulant. Thromb Res 125(6):538–544PubMedCrossRefGoogle Scholar
  57. 57.
    Harenberg J, Giese C, Marx S, Krämer R (2012) Determination of dabigatran in human plasma samples. Semin Thromb Hemost 38(1):16–22PubMedCrossRefGoogle Scholar
  58. 58.
    Mismetti P, Laporte S (2010) New oral antithrombotics: a need for laboratory monitoring. J Thromb Haemost 8(4):621–626PubMedCrossRefGoogle Scholar
  59. 59.
    Harder S (2012) Renal profiles of anticoagulants. J Clin Pharmacol 52(7):964–975PubMedCrossRefGoogle Scholar
  60. 60.
    Harper P et al (2012) Bleeding risk with dabigatran in the frail elderly. N Engl J Med 366(9):864–866PubMedCrossRefGoogle Scholar
  61. 61.
    Legrand M et al (2011) The use of dabigatran in elderly patients. Arch Intern Med 171(14):1285–1286PubMedCrossRefGoogle Scholar
  62. 62.
    Paré G, Erikkson N, Lehr T et al (2012) RE-LY-genetics: genetic determinants of dabigatran plasma levels and their relation to clinical response. European Society of Cardiology Congress, MunichGoogle Scholar
  63. 63.
    Cavallari LH, Shin J, Perera MA (2011) Role of pharmacogenomics in the management of traditional and novel oral anticoagulants. Pharmacotherapy 31(12):1192–1207PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Helen Mani
    • 1
  • Alexander Kasper
    • 1
  • Edelgard Lindhoff-Last
    • 1
  1. 1.Division of Vascular Medicine, Department of Internal MedicineJohann Wolfgang Goethe-University Hospital Frankfurt/MainFrankfurtGermany

Personalised recommendations